When caring for a client on intravenous magnesium sulfate for preeclampsia, which urinary output necessitates notifying the healthcare provider?

In the context of monitoring a client receiving intravenous magnesium sulfate for preeclampsia, a decrease in urinary output is indicative of potential renal impairment, which can complicate the management of both preeclampsia and magnesium toxicity. Magnesium sulfate can elevate magnesium levels, and impaired renal function can lead to an accumulation of magnesium.

A urinary output of less than 100 mL in 4 hours is significant enough to warrant immediate attention from the healthcare provider. This threshold is critical because it suggests possible oliguria, which could indicate the onset of renal failure or worsening of the patient's condition. Close monitoring of renal function is essential in patients receiving this treatment, as they are often at risk for complications related to both preeclampsia and the effects of magnesium sulfate.

In contrast, while lower outputs may also indicate issues, the specific threshold of less than 100 mL aligns closely with common clinical guidelines that highlight the importance of prompt intervention when urinary output falls below this level. Immediate communication with the healthcare provider allows for timely assessment and potential adjustment of treatment to prevent further complications.